An Engineering‐Editable Hybrid Membrane‑Camouflaged DNA Origami Drug Enables Checkpoint Blockade and Immune Activation for Triple‐Negative Breast Cancer Immunotherapy
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.7162372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Xiaqing Gong und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors, Antineoplastic Agents. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Natural Science Foundation of Anhui Province, University Natural Science Research Key Project of Anhui Province, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
The clinical response to immunotherapy in triple‐negative breast cancer (TNBC) is often limited by the immunosuppressive microenvironment, immune cell exhaustion, and multidrug resistance. Through a high‐throughput screen of 2,500 FDA‐approved drugs using a three‐dimensional tumor organoid platform, we identified thonzonium bromide (THO) as an inducer of gasdermin D (GSDMD)‐mediated pyroptosis, which results in the release of damage‐associated molecular patterns (DAMPs) to activate antitumor immunity. To achieve targeted delivery, we designed a core–shell‐structured biomimetic nanoparticle (THO/AMT‐si NP) consisting of a core formed by tetrahedral DNA (TDN NPs) constructed using DNA origami technology, which is loaded with THO and P‐gp siRNA, and an outer layer coated with a programmatically designed hybrid membrane (AREP). These findings indicate that THO/AMT‐Si NPs can effectively target TNBC tumors, convert “cold” tumors into “hot” tumors by inducing pyroptosis in cancer cells, reverse immune cell exhaustion, and simultaneously overcome cancer cell multidrug resistance, thereby achieving synergistic inhibition of tumor growth and metastasis. In summary, this biomimetic nanomedicine enhances immunotherapy for TNBC by combining synergistic cascade targeting, immune checkpoint blockade, and thermosis‐mediated immune activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Anhui Medical University, Hefei, China.
ORCID-Profile: Mingming Song
Förderung
- Natural Science Foundation of Anhui Province
- University Natural Science Research Key Project of Anhui Province
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Gong, X., Yuan, H., Fang, Y., & Song, M. (2026). An Engineering‐Editable Hybrid Membrane‑Camouflaged DNA Origami Drug Enables Checkpoint Blockade and Immune Activation for Triple‐Negative Breast Cancer Immunotherapy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.7162372
Vancouver
Gong X, Yuan H, Fang Y, Song M. An Engineering‐Editable Hybrid Membrane‑Camouflaged DNA Origami Drug Enables Checkpoint Blockade and Immune Activation for Triple‐Negative Breast Cancer Immunotherapy. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.7162372
BibTeX
@article{Gong2026,
author = {Gong, Xiaqing and Yuan, Han and Fang, Ying and Song, Mingming},
title = {An Engineering‐Editable Hybrid Membrane‑Camouflaged DNA Origami Drug Enables Checkpoint Blockade and Immune Activation for Triple‐Negative Breast Cancer Immunotherapy},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.7162372}
}
EUVIMED